Polyclonal Antibodies Derived from Transchromosomic Bovines Vaccinated with the Recombinant F1-V Vaccine Increase Bacterial Opsonization In Vitro and Protect Mice from Pneumonic Plague
Authors:
- Sergei S. BiryukovSBSergei S. Biryukov
- Hua WuHWHua Wu
- Jennifer L. DankmeyerJDJennifer L. Dankmeyer
- Nathaniel O. RillNRNathaniel O. Rill
- Christopher P. KlimkoCKChristopher P. Klimko
- Kristi A. EglandKEKristi A. Egland
- Jennifer L. ShoeJSJennifer L. Shoe
- Melissa HunterMHMelissa Hunter
- David P. FettererDFDavid P. Fetterer
- Ju QiuJQJu Qiu
- Michael L. DaviesMDMichael L. Davies
- Christoph L. BauschCBChristoph L. Bausch
Open Access
- 8 May 2023
- journal article
- research article
- Published by MDPI AG in Antibodies
- Vol. 12 (2) , 33
Abstract
Plague is an ancient disease that continues to be of concern to both the public health and biodefense research communities. Pneumonic plague is caused by hematogenous spread of Yersinia pestis bacteria from a ruptured bubo to the lungs or by directly inhaling aerosolized bacteria. The fatality rate associated with pneumonic plague is significant unless effective antibiotic therapy is initiated soon after an early and accurate diagnosis is made. As with all bacterial pathogens, drug resistance is a primary concern when developing strategies to combat these Yersinia pestis infections in the future. While there has been significant progress in vaccine development, no FDA-approved vaccine strategy exists; thus, other medical countermeasures are needed. Antibody treatment has been shown to be effective in animal models of plague. We produced fully human polyclonal antibodies in transchromosomic bovines vaccinated with the recombinant F1-V plague vaccine. The resulting human antibodies opsonized Y. pestis bacteria in the presence of RAW264.7 cells and afforded significant protection to BALB/c mice after exposure to aerosolized Y. pestis. These data demonstrate the utility of this technology to produce large quantities of non-immunogenic anti-plague human antibodies to prevent or possibly treat pneumonic plague in human.Keywords
Funding Information
- DOD’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) (MCDC 18-05-19-002)
This publication has 81 references indexed in Scilit:
- Effects of temperature on the transmission of Yersinia Pestis by the flea, Xenopsylla Cheopis, in the late phase periodParasites & Vectors, 2011
- Recombinant (F1+V) vaccine protects cynomolgus macaques against pneumonic plagueVaccine, 2011
- Human Anti-Plague Monoclonal Antibodies Protect Mice from Yersinia pestis in a Bubonic Plague ModelPLOS ONE, 2010
- Amino acid and structural variability of Yersinia pestis LcrV proteinInfection, Genetics and Evolution, 2010
- Dual-Function Antibodies to Yersinia pestis LcrV Required for Pulmonary Clearance of PlagueClinical and Vaccine Immunology, 2009
- In Vitro Intracellular Trafficking of Virulence Antigen during Infection by Yersinia pestisPLOS ONE, 2009
- Vaccination of Mice with a Yop Translocon Complex Elicits Antibodies That Are Protective against Infection with F1 − Yersinia pestisInfection and Immunity, 2008
- Induction of the Yersinia Type 3 Secretion System as an All-or-None PhenomenonJournal of Molecular Biology, 2007
- Effects of Psa and F1 on the Adhesive and Invasive Interactions ofYersinia pestiswith Human Respiratory Tract Epithelial CellsInfection and Immunity, 2006
- Administration of Antibody to the Lung Protects Mice against Pneumonic PlagueInfection and Immunity, 2006